MXPA03009846A - Derivados de triazol inhibidores de cinasa y usos de los mismos. - Google Patents

Derivados de triazol inhibidores de cinasa y usos de los mismos.

Info

Publication number
MXPA03009846A
MXPA03009846A MXPA03009846A MXPA03009846A MXPA03009846A MX PA03009846 A MXPA03009846 A MX PA03009846A MX PA03009846 A MXPA03009846 A MX PA03009846A MX PA03009846 A MXPA03009846 A MX PA03009846A MX PA03009846 A MXPA03009846 A MX PA03009846A
Authority
MX
Mexico
Prior art keywords
kinase inhibitors
triazole
derived kinase
compounds
useful
Prior art date
Application number
MXPA03009846A
Other languages
English (en)
Inventor
Maltais Francois
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of MXPA03009846A publication Critical patent/MXPA03009846A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

Se describen aqui compuestos que son utiles como inhibidores de la proteina cinasa, que tienen la formula: en donde Ht, R2, T y m, son como se describio en la especificacion. Los compuestos son utiles para tratar enfermedades en mamiferos, que son aliviadas por un inhibidor de la proteina cinasa, particularmente enfermedades tales como el cancer, trastornos inflamatorios, restenosis y enfermedad cardiovascular.
MXPA03009846A 2001-04-27 2002-04-26 Derivados de triazol inhibidores de cinasa y usos de los mismos. MXPA03009846A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28720401P 2001-04-27 2001-04-27
PCT/US2002/013396 WO2002088097A1 (en) 2001-04-27 2002-04-26 Triazole-derived kinase inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
MXPA03009846A true MXPA03009846A (es) 2004-05-05

Family

ID=23101887

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03009846A MXPA03009846A (es) 2001-04-27 2002-04-26 Derivados de triazol inhibidores de cinasa y usos de los mismos.

Country Status (6)

Country Link
US (2) US6962936B2 (es)
EP (1) EP1390353A1 (es)
JP (1) JP2004532234A (es)
CA (1) CA2445568A1 (es)
MX (1) MXPA03009846A (es)
WO (1) WO2002088097A1 (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1207864A2 (en) * 2000-02-05 2002-05-29 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of erk
US6727364B2 (en) * 2001-04-30 2004-04-27 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
US20050214343A1 (en) * 2002-07-18 2005-09-29 Patrice Tremble Medical devices comprising a protein-tyrosine kinase inhibitor to inhibit restonosis
UA80295C2 (en) 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
US20060183897A1 (en) * 2003-03-18 2006-08-17 Chakravarty Prasun K Biaryl substituted triazoles as sodium channel blockers
AR044503A1 (es) * 2003-03-18 2005-09-14 Merck & Co Inc Triazoles sustituidos con biarilo como bloqueantes del canal de sodio
EP1611123B8 (en) 2003-04-09 2013-11-13 Exelixis, Inc. Tie-2 modulators and methods of use
DE602004012578T2 (de) * 2003-08-15 2008-12-11 Vertex Pharmaceuticals Inc., Cambridge Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
DE10354060A1 (de) * 2003-11-19 2005-06-02 Merck Patent Gmbh Pyrrolderivate
EP1848428A4 (en) 2005-02-18 2012-04-18 Neurogen Corp THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGS
US20060252807A1 (en) * 2005-04-22 2006-11-09 Kalypsys, Inc. Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders
CN100334084C (zh) * 2005-04-26 2007-08-29 武汉大学 联***化合物及其制备方法和用途
WO2007014198A1 (en) * 2005-07-25 2007-02-01 Synta Pharmaceuticals Corp. 1, 2, 3 -triazoles inhibitors of tubulin polymerization for the treatment of poliferative disorders
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
BRPI0620341A2 (pt) * 2005-12-23 2011-11-08 Smithkline Beecham Corparation azaindóis inibidores de cinases aurora
KR20080103996A (ko) 2006-02-16 2008-11-28 쉐링 코포레이션 Ｅｒｋ 억제제로서 피롤리딘 유도체
US20080081210A1 (en) * 2006-09-29 2008-04-03 General Electric Company Authenticatable articles and methods therefor
US20080081913A1 (en) * 2006-09-29 2008-04-03 General Electric Company Benzoxazole and benzothiazole compounds and methods therefor
US10765277B2 (en) 2006-12-12 2020-09-08 Omachron Intellectual Property Inc. Configuration of a surface cleaning apparatus
GB2457420B (en) 2006-12-12 2012-01-04 Gbd Corp Convertible surface cleaning apparatus
US8950039B2 (en) 2009-03-11 2015-02-10 G.B.D. Corp. Configuration of a surface cleaning apparatus
UY30892A1 (es) * 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
JP5580732B2 (ja) 2007-04-03 2014-08-27 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 置換ベンゼン殺菌・殺カビ剤
US11751733B2 (en) 2007-08-29 2023-09-12 Omachron Intellectual Property Inc. Portable surface cleaning apparatus
MY150059A (en) * 2007-10-11 2013-11-29 Astrazeneca Ab Pyrrolo [2,3-d] pyrimidin derivatives as protein kinase b inhibitors
RU2525389C2 (ru) 2008-02-21 2014-08-10 Мерк Шарп И Доум Корп. Соединения, которые являются ингибиторами erk
KR101014351B1 (ko) 2008-08-04 2011-02-15 한국생명공학연구원 세포외 신호조절 키나제의 활성을 저해하는트리아졸릴-벤즈아미드 유도체 또는 이의 약학적으로허용가능한 염을 유효성분으로 함유하는 암 또는 심혈관계질환의 예방 또는 치료용 조성물
NZ594064A (en) * 2009-01-30 2012-08-31 Glaxosmithkline Llc Crystalline n-{ (1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl} -5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
US9211044B2 (en) 2011-03-04 2015-12-15 Omachron Intellectual Property Inc. Compact surface cleaning apparatus
CA2674761C (en) 2009-03-13 2016-10-04 G.B.D. Corp. Surface cleaning apparatus with different cleaning configurations
US9427122B2 (en) 2009-03-13 2016-08-30 Omachron Intellectual Property Inc. Surface cleaning apparatus
US9226633B2 (en) 2009-03-13 2016-01-05 Omachron Intellectual Property Inc. Surface cleaning apparatus
US9480373B2 (en) 2009-03-13 2016-11-01 Omachron Intellectual Property Inc. Surface cleaning apparatus
US11690489B2 (en) 2009-03-13 2023-07-04 Omachron Intellectual Property Inc. Surface cleaning apparatus with an external dirt chamber
US9392916B2 (en) 2009-03-13 2016-07-19 Omachron Intellectual Property Inc. Surface cleaning apparatus
CA2967272C (en) 2009-03-13 2018-01-02 Omachron Intellectual Property Inc. Hand vacuum cleaner
CA2674376A1 (en) 2009-03-13 2010-09-13 G.B.D. Corp. Surface cleaning apparatus with different cleaning configurations
US9138114B2 (en) 2009-03-13 2015-09-22 Omachron Intellectual Property Inc. Surface cleaning apparatus
US9198551B2 (en) 2013-02-28 2015-12-01 Omachron Intellectual Property Inc. Surface cleaning apparatus
US9591953B2 (en) 2009-03-13 2017-03-14 Omachron Intellectual Property Inc. Surface cleaning apparatus
US11612288B2 (en) 2009-03-13 2023-03-28 Omachron Intellectual Property Inc. Surface cleaning apparatus
EP2413696A4 (en) * 2009-04-03 2012-10-24 Sinai School Medicine COMPOSITIONS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
US20110212994A1 (en) * 2009-06-26 2011-09-01 Brian Clem Small Molecule Choline Kinase Inhibitors, Screening Assays, and Methods for Safe and Effective Treatment of Neoplastic Disorders
US8875340B2 (en) 2010-03-12 2014-11-04 G.B.D. Corp. Surface cleaning apparatus with enhanced operability
CN102174031B (zh) * 2011-03-24 2013-05-08 南开大学 一类1,2,3-噻二唑联-1,3,4-噻二唑类化合物及其制备方法和用途
TWI582084B (zh) 2011-10-07 2017-05-11 武田藥品工業股份有限公司 雜環化合物
US9456721B2 (en) 2013-02-28 2016-10-04 Omachron Intellectual Property Inc. Surface cleaning apparatus
US9314138B2 (en) 2013-02-28 2016-04-19 Omachron Intellectual Property Inc. Surface cleaning apparatus
US9215960B2 (en) 2013-02-28 2015-12-22 Omachron Intellectual Property Inc. Surface cleaning apparatus
US9364127B2 (en) 2013-02-28 2016-06-14 Omachron Intellectual Property Inc. Surface cleaning apparatus
WO2014152018A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydrocyclopentapyrroles, their preparation and use
WO2014151959A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
WO2014151936A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles, their preparation and use
DK2968304T3 (en) * 2013-03-14 2019-01-28 Univ Columbia 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE.
US10626095B2 (en) * 2013-07-17 2020-04-21 Otsuka Pharmaceutical Co., Ltd. Cyanotriazole compounds
CN111393434B (zh) 2014-04-30 2022-11-04 哥伦比亚大学董事会 取代的4-苯基哌啶及其制备和用途
EP3300500B9 (en) * 2015-05-20 2021-01-13 Amgen Inc. Triazole agonists of the apj receptor
US10729295B2 (en) 2016-08-29 2020-08-04 Omachron Intellectual Property Inc. Surface cleaning apparatus
US10405711B2 (en) 2016-08-29 2019-09-10 Omachron Intellectual Property Inc. Surface cleaning apparatus
US10413141B2 (en) 2016-08-29 2019-09-17 Omachron Intellectual Property Inc. Surface cleaning apparatus
US10433689B2 (en) 2016-08-29 2019-10-08 Omachron Intellectual Property Inc. Surface cleaning apparatus
US10136780B2 (en) 2016-08-29 2018-11-27 Omachron Intellectual Property Inc. Surface cleaning apparatus
US10441125B2 (en) 2016-08-29 2019-10-15 Omachron Intellectual Property Inc. Surface cleaning apparatus
US10136779B2 (en) 2016-08-29 2018-11-27 Omachron Intellectual Property Inc. Surface cleaning apparatus
US9962050B2 (en) 2016-08-29 2018-05-08 Omachron Intellectual Property Inc. Surface cleaning apparatus
US10321794B2 (en) 2016-08-29 2019-06-18 Omachron Intellectual Property Inc. Surface cleaning apparatus
US11478117B2 (en) 2016-08-29 2022-10-25 Omachron Intellectual Property Inc. Surface cleaning apparatus
US10441124B2 (en) 2016-08-29 2019-10-15 Omachron Intellectual Property Inc. Surface cleaning apparatus
US10292550B2 (en) 2016-08-29 2019-05-21 Omachron Intellectual Property Inc. Surface cleaning apparatus
IT201600092051A1 (it) * 2016-09-13 2018-03-13 Alessandro Antonelli Composto medicale per il trattamento di tumori della tiroide
KR20230156818A (ko) * 2016-10-03 2023-11-14 시질론 테라퓨틱스, 인크. 화합물, 장치, 및 이의 용도
WO2018093580A1 (en) * 2016-11-16 2018-05-24 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
WO2019042267A1 (zh) * 2017-08-28 2019-03-07 中国医学科学院药物研究所 吡咯-2-甲酰胺类化合物及其制备方法和用途
TW202340155A (zh) * 2017-12-29 2023-10-16 美商拜奧馬林製藥公司 用於疾病治療之乙醇酸酯氧化酶抑制劑
US11807624B2 (en) 2018-05-01 2023-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the APJ receptor
US11739078B2 (en) * 2019-02-22 2023-08-29 Insilico Medicine Ip Limited Methods of inhibiting kinases
EP3986863A4 (en) * 2019-06-19 2023-01-18 BioMarin Pharmaceutical Inc. GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE
US11530197B2 (en) 2021-02-24 2022-12-20 Insilico Medicine Ip Limited Analogs for the treatment of disease
WO2022179529A1 (en) * 2021-02-24 2022-09-01 Insilico Medicine Ip Limited Analogs for the treatment of disease
CN113069451B (zh) * 2021-04-02 2022-08-09 苏州大学 一种吡咯-2-磺酰胺化合物的制备方法及其在制备抗肿瘤药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559137A (en) 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
US6087381A (en) * 1997-05-22 2000-07-11 G. D. Searle & Company Pyrazole derivatives as p38 kinase inhibitors
IL145756A0 (en) * 2000-02-05 2002-07-25 Vertex Pharma Pyrazole derivatives and pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
WO2002088097A1 (en) 2002-11-07
US20050272789A1 (en) 2005-12-08
US6962936B2 (en) 2005-11-08
US20030158238A1 (en) 2003-08-21
CA2445568A1 (en) 2002-11-07
EP1390353A1 (en) 2004-02-25
JP2004532234A (ja) 2004-10-21

Similar Documents

Publication Publication Date Title
MXPA03009846A (es) Derivados de triazol inhibidores de cinasa y usos de los mismos.
AU2002321910A1 (en) Pyrazole-derived kinase inhibitors and uses thereof
WO2002088090A3 (en) Pyrazole derived kinase inhibitors
MXPA04001088A (es) Derivados de pirazol como inhibidores de cinasa y uso de los mismos.
HK1052934A1 (en) Isoxazoles and their use as inhibitors of erk
LT2001103A (en) Pyrazole compositions useful as inhibitors of erk
WO2001056993A3 (en) Pyrazole compositions useful as inhibitors of erk
AP2003002853A0 (en) Heterocyclic inhibitors of ERK2 and uses thereof
CY1109006T1 (el) Παραγωγα πουρινης ως αναστολεις κινασης
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
RS95404A (en) Thiazolidinones and the use thereof as polo-like kinase inhibitors
PL372926A1 (en) Piperidine-pyridazones and phthalazones as pde4 inhibitors
ATE420879T1 (de) Indolizine als kinaseproteinhemmer
EP1436286A4 (en) FUMAGILLOL DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
AP2005003350A0 (en) 3-(3,5-dioxo-4,5-dihydro-3H-(1,2,4) triazin-2-yl)-benzamide derivatives as p2X7 -inhibitors for the treatment of inflammatory diseases.
MY142988A (en) Novel aminobenzophenone compounds
WO2007120333A3 (en) Tetracyclic kinase inhibitors
AU3864500A (en) Substituted aza-oxindole derivatives
MX2007002525A (es) Compuestos de difeniletileno y usos de los mismos.
UA85505C2 (en) Kinase inhibitors
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
NO20081292L (no) Pentasykliske kinaseinhibitorer
BRPI0415390A (pt) compostos de pirazinona substituìda para o tratamento da inflamação
MX2007013306A (es) Nuevas tiazolidinonas sin nitrogeno basico, su produccion y su uso como agentes farmaceuticos.

Legal Events

Date Code Title Description
FG Grant or registration